Reviva Pharmaceuticals Holdings Inc — Financial Statements (NASDAQ:RVPH) | MetaTrader

Open full chart

新闻

Vocal biomarker study supports brilaroxazine’s efficacy in schizophrenia

Chardan Capital 开始对 Reviva Pharmaceuticals 股票进行覆盖并给予买入评级

Chardan Capital assumes coverage on Reviva Pharmaceuticals stock with Buy rating

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—12/30/25 - TipRanks.com

H.C. Wainwright 重申 Reviva Pharmaceuticals 为"买入"评级

Reviva Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.16%

美国股市上涨；截至收盘道琼斯工业平均指数上涨0.16%

Reviva制药公司股价暴跌，因FDA要求进行第二次三期临床试验

Reviva Pharmaceuticals stock plunges after FDA requests second Phase 3 trial

FDA建议Reviva的精神分裂症药物进行第二次三期临床试验

FDA recommends second phase 3 trial for Reviva’s schizophrenia drug